All right. Welcome, everyone, to Jefferies 2026 Global Healthcare Conference in London. My name is Roger Song, senior analyst, covers biotech in the U.S. It is my great pleasure to have the fireside chat with Novavax. We have the full crew here. John Jacobs, CEO.
Thank you, Roger.
Jim Kelly, CFO.
Thanks, Roger.
Elaine O'Hara, the Chief Strategy Officer. We have Bob Walker, Head of R&D. Welcome, gentlemen, and then lady. Maybe, John, why not you start with, particularly for the investor who are relatively new to Novavax
Yeah
which they should not be. Since you joined Novavax two years ago, launched a new strategy as a new CEO, what you have been achieved, what's the future look like, and why you're excited?
Roger, it's been a remarkable transformation of the company that we're very excited about. We've changed the company from a vaccine company focused on marketing its one asset at the time, which was a vaccine for COVID, and taking this technology platform, which is the reason I came here, phenomenal platform, and looking to share that more with the world through out-licensure and partnering. So we converted the company from a fully integrated global company selling one product in a pandemic to a company that out-licensed our tech with the goal of building value and revenue through partnering. I'm not sure if we lost audio here, guys, but we'll
Should be all right.
I think you have it.
Okay.
Look, we believe our technology can underpin a wide variety of vaccines in viral and bacterial targets and infectious disease, where we started and where we have proof of concept, and potentially in oncology, where we're in the stages of early exploration on how our technology might fit into that emerging ecosystem with vaccines. When we look back just on 2026, we're very proud of our accomplishments as a team. Year two of this new strategy that we launched, we've had some significant milestones and achievements, including bringing Pfizer in as a new partner with a half billion dollar headline and potential milestones across two fields and a $30 million upfront for Pfizer to engage with and explore our technology, and hopefully bring forward more than one asset to help people in the future as a great partner.
We just earned, in the last month or so, a $125 million milestone from our ongoing partnership with Sanofi for their clinical initiation of a combination COVID-flu vaccine with their world-leading flu vaccine and our differentiated COVID vaccine, non-mRNA protein-based. That trial started in Europe. We earned that milestone. They also indicated their intention to start a combination vaccine trial in the U.S. market. As a reminder for our audience, should they achieve a first sale of a combination vaccine with our COVID vaccine in the U.S., we would be eligible to earn a $225 million milestone and ongoing royalties for potentially decades after the launch of these products.
We also, through the course of 2026, signed up additional initial partners through MTAs, or material transfer agreements, where these companies get to explore our technology in their own laboratories with the hopes that those too may turn into eventually license agreements for the company, similar to those of Pfizer and/or Sanofi. In addition, Roger, despite reducing our expenses between 80% and 90% over the last few years, we've maintained our capabilities to drive R&D. We make select investments in our R&D, and we use that to help fuel this partnering model.
Through the year, we have advanced our experiments with existing commercialized vaccines by adding our Matrix-M to many of those methodically, generating data that Elaine and her team can then go into potential partners with, existing partners with, and we can show them what their assets or their portfolio targets look like when they add our technology to hopefully foster more partnerships. Last but not least, we are advancing our own C. difficile vaccine with intention of being in the clinic as early as 2027, and again, with the primary intention about licensing that and generating more partnerships. That is 2026. We can talk later about what is ahead on catalysts, but very excited about where we are two years into this strategy right now.
Excellent.
Thank you.
Okay. This is a great overview. Then let us talk each section in order. Novavax is no longer a one-product company, and then you have platform, you have a lot of partnership. COVID flu will still be the near-term value driver. Let us maybe just zoom in a little bit on that end. Take a step back. I think we have been through COVID, but it still persists.
Yes.
How we think about the global COVID market, and then particularly in the context of the potential combination with the flu and the COVID? Maybe who-
Important question, Roger. Jim, you want to take that?
Yeah.
Well, certainly. I think one of your initial observations there that we are a company with multiple layers of value creation from commercial products live in the market, Nuvaxovid with Sanofi, to now a phase III combination CIC influenza product being launched by Sanofi, and then a full pipeline full of catalysts. There's a lot here in the coming quarters and years to drive value creation. In particular, when we look at the COVID and the flu marketplace, I think people might remember last year was a choppy market. This year, it looks flat to up. It looks like we've seen great stabilization, and I'm referencing U.S. market statistics at this time. When we think about the COVID and the flu markets, and you add their global revenues together, you have over a $10 billion marketplace.
I'm purposely describing both because what the market is demanding is better compliance and combination therapy, combination vaccines. Sanofi, with their Phase 3, intends to be an early entrant, an early mover in that marketplace, which is incredibly exciting when you consider they're taking our Nuvaxovid and combining it with one, perhaps two, of their market-leading enhanced flu products. Think about high-dose Fluzone and Flublok. They have almost two-thirds market share in the enhanced flu, which is the exact use case and vaccination case for Nuvaxovid. This is a great partnership. What they have the ability to do in the coming years, continue to methodically build Nuvaxovid en route to combining it with that market-leading flu franchise. That's what we're excited about.
All right, to the point of the market sizing, what we're seeing with COVID in particular, the market last year was $6.8 billion globally, of which $2.9 billion was in the U.S., and then the remaining ex-U.S. Year to date, season to date, in the U.S., it's flattish. It's like single-digit declines, but recent weeks exceed prior year. We expect a firming of the U.S. market for COVID. On the ex-U.S. basis, we're hitting the end of some of those legacy APAs, and in Europe in particular, the Pfizer agreement, the last year is this year. I think we're going to get a very good read on the size of the European market this year, absent that agreement in Europe, and then next year, I think a great run rate. Either way, I think you got a $4 billion or $5 billion stable market.
That's what the marketplace looks like today.
Awesome. This year is the first year your partner, Sanofi, is having a full year commercialization. I know it is a learning year for them. What have you observed from your partner, and what have they done, and any performance you can, in the context of it, that you can discuss?
Elaine, you want to take that one?
Yeah, thanks, John. At the macro level, we're very excited about the commitment that Sanofi has shown since we entered into our collaborative license agreement back in 2024. Every step of the way, we have had a very profound partnership, underscored by our announcement early November that they were entering into their Phase III study in Europe. That's an immunogenicity study for the combination influenza and COVID program in people over 60, and also their recent statement that they would be initiating a Phase III study in the U.S. in 2027. Both of those events are extremely important to us. Obviously, we have our milestone that's associated with that, as both John and Jim mentioned, of $225 million for the first sale, when they are commercialized in the U.S.
Very exciting times, and we've literally been working hand-in-hand, hip-by-hip over the last couple of years to make sure that the products are successful and come to market, and then, of course, that we achieve our milestones as well. Specific to this season, again, a nice year. We're happy with what we see. A good share so far. Sanofi has initiated their contracting late last year, which is typical, and are in all major retailers in the U.S. in 2026 for the season, and have run fairly substantial pilots across the retailers. What we see is Nuvaxovid is quite promotionally sensitive. So in the pilots that they ran, we saw reordering for Nuvaxovid product, and in specific areas, a share that was quite significant as well, where Nuvaxovid was being preferentially offered in those retail settings.
Again, with the investment of direct-to-consumer advertising, best-in-class sales force, best-in-class national accounts team, really a nice year this year. Obviously, together, our goal is to make sure that we drive awareness of Nuvaxovid in both the U.S. and ex-U.S. markets. We've seen some add-ons as well from an ex-U.S. perspective as they start to expand globally for Nuvaxovid as well. All with the, as I said, leading up to the macro level of getting to that point where, when you're launching your combination influenza and CIC program, you can be very successful. Very happy with what we see and delighted with the partnership, and happy to continue over the next several years.
Yeah, and we'll look to see them work to build a material share over time, Roger. It's going to be a methodical approach. They have a foothold now in the U.S. to start, and we expect to see them build upon that year after year. In summary, Sanofi's leaning in, not away. They're making the investments in DTC, in advertising, in building awareness, in piloting different types of approaches with U.S. retail, in approaching tenders to try to win those in the rest of world outside of the U.S., because it's a global marketplace, and investing in the combination COVID flu program and paying us those milestones, spending on those clinical trials. That's one of the elements of our strategy.
Sanofi, or with Pfizer, or with other intended future partners that we have, that we leverage their expertise, their resources, and their scale to help us advance our technology more quickly and have a vision where we have multiple vaccines across multiple portfolios with multiple partners, making a huge impact and a legacy on global health. That's the vision.
Got it. Okay, great. One specific question related to the U.S. phase III. Would that be an immunogenicity-driven trial, or is it a more field efficacy trial, number one? Number two is, how much those learnings, experience marketing the COVID alone, and then when the CIC or the COVID-flu vaccine is coming to the market, then they can leverage that learning to expand rapidly to get that market share.
Two-part question. Bob, you want to take the first part on the potential study design in the U.S., and Elaine can cover the commercial piece there.
Yeah, sure. We just reiterate how excited we are that Sanofi has publicly stated, has actually initiated their European phase III trial, and publicly stated their intent to initiate a phase III trial in the U.S. next year. Now, in terms of the design of the phase III study in the U.S., it is worth reminding folks that we do not have access to Sanofi's plans, activities, timelines related to CIC, other than what they publicly state or what they may confirm to us. Cannot really comment on the specific design, but we are excited and we are really looking forward to-
What we can say, Bob, right, is what they have said publicly, that they have intention to start a combination clinical trial in the U.S. market next year. Those are their public comments, so we can repeat that for the audience here who might not have heard them say that. That is their intention, and it would be logical to assume they have an idea of regulatory pathway, or they would not be saying that in their public commentary. We are excited about their commitment, already starting the trial and running it in Europe, and their stated commitment to the U.S. market next year.
Yeah. Okay, good. When the CIC is coming to the market, how much learning you can leverage from the flu, from the COVID marketing, and they can rapidly going to get a market share in the U.S. and ex-U.S.?
Yeah, no, it's a great question, and they have stated that they see room for three to four products in their armamentarium to address respiratory illness. So, standalone flu, standalone COVID, and potentially two combination influenza and COVID programs or products, one with Flublok, as Jim mentioned earlier, and one with Fluzone High-Dose, right? So, there is a space for all of those products in the marketplace. I think what's really interesting is the driving of the trend, obviously, towards a combination product. To answer your question, Roger, exactly, they have profound experience. They're number one flu vaccine company globally, right? Being able to address a need for a potential non-mRNA flu and COVID vaccine, I think, is incredibly important, both in the U.S. and ex-U.S.
There's a nice opportunity there for a differentiated portfolio of products, which is exactly what Sanofi intended to do from a strategic perspective.
Okay. Very good. I think we spent a fair amount of time on the COVID-flu because that is the near-term kind of value driver. It's not lost on us, you are shifting more on the partnership strategy, and also you're building your own internal pipeline. On the partnership, you already signed a lot of the MTA, and some of them already convert, including Pfizer. That's very encouraging to see. What's next, right? How are you going to Seems you are expanding from infectious disease to the oncology. What drove that, and what's the status of that? Because we haven't seen anything coming from the cancer side yet.
Yeah, I'll let Elaine put some more context around these things. On the partnering side, it's important that we have four existing partners right now. We have Takeda, we have Sanofi, we have Pfizer, we have Serum Institute of India. What we see and what we have seen to date are that as our partners get exposed more and more to our technology, the interest continues to be strong or even grow, right? You've seen Sanofi continue to lean in and invest to move forward with the other pieces of that contractual agreement that was signed just over two years ago now, right? We've seen remarkable interest in our tech from existing as well as potential new partners.
Elaine, you might want to comment on our process that we take regarding generation of data and conversations with potential partnerships, and then next steps potentially from there and how that might evolve.
Yeah, absolutely. Maybe I'll just focus in a little bit on the question you asked as it relates to oncology. Obviously, Matrix-M is technically part of a marketed product, so it's got a substantial safety and efficacy database associated with it, so it's a trusted adjuvant. Several years ago, we started to think about the utility of Matrix-M in oncology as a way to potentially unlock value in the oncologic setting, create more durable, long-lasting CD8 T cell responses. Cellular response is really what everybody's interested when it comes to oncology vaccines, obviously. We initiated some experimentation internally and saw very positive data, again, preclinical data. We also had a relationship with an external company, generated some positive data there, and the combination of some of these things then also led us to an MTA with an actual oncology company.
They're in the midst of their experimentation work pre-clinically as well. Very excited about that opportunity and what lies ahead. In general, when we look at MTAs, that's a process whereby we engage with a company, and they do experimentation work with our Matrix-M platform, again, sort of hinting back at the safety database, efficacy, et cetera. It's an adjuvant that can work obviously very well in infectious disease, and we also have MTAs with other companies in infectious disease, and now we're systematically exploring the oncology opportunity as well. Very interested to see what's going to come out of our experimentation set, both internally as well as externally throughout 2027.
Roger, it's obviously our intent that as many of these interactions as possible would turn into license agreements in the future. But obviously, not everything that they try or we try will work. Not every MTA will turn into a deal. But what we really like about our strategy is we continue to put multiple opportunities on the table to potentially succeed. In biotech, you just need a few of those things to succeed over time to really start to build hopefully meaningful value. It's our intention to have future partners emerge through these efforts, and we'll keep working on it every day.
Okay. Yeah, multiple shots on goal. That's the name of the game.
Yeah, that's the goal.
Yes. Then, you did sign a partnership with Pfizer coming out of the MTA.
Right, so that's another example of that, right?
Just forward-looking, right? So it's not like you have official guidance. Should we expect to see something coming from 2027, or the timeline-wise, because you already have, I forgot, you may have how many MTA already ongoing. It's been a while, right? How long usually going to take you to have a very tangible partnership? Not saying everything going to convert to the partnership, just-
Again, Elaine can provide some additional color, but we won't provide forecasts or estimates on timing there. It's a good question. Everybody wants to know. We'll always know a lot more than we can share with you on these types of things. But because we don't control the final outcome on some of those, if it's a partner on their side, we don't want to predict timing.
Yeah.
But what we can say is we've seen remarkable interest in our technology, and that's very strong and even getting stronger as we move through the year, the last couple of years of our strategy. So, very excited about what we see. Anything to add, Elaine, on that?
No, I think we're really looking forward to 2027, I think, in terms of some of these engagements. What we're delighted to see, maybe to answer your question, is for our existing partners, we're delighted to see their interest in the Matrix-M platform. Typically, we're seeing an even deeper interest. First MTA potentially generating more, and with some of our new partners, again, we're still looking forward to seeing what's going to come out in 2027. But very good, significant interest in Matrix-M all around.
Okay. Yeah.
One of many catalysts to look for in 2027 and beyond would be additional partners potentially coming on board for Novavax, as well as potentially existing partners deepening their relationship, leaning in even further, and continuing to invest in our technology and advance these relationships.
Okay. Yeah. I hope you just say 2027, but you did say 2027 and beyond. But I think people, as a company, have that partnership strategy, you want to see those partnership getting broader in the future, right?
Continuously over time, not just in the next four quarters. We won't promise a specific timing on any partnership that comes, and we will be limited in what we can say about certain partnerships. We have to protect the intellectual property and the integrity of these agreements with our partners. Unlike some other companies where they can show you a clinical catalyst that comes and everyone sees it and can model it, we have to guard the confidentiality of these discussions and relationships as part of our capital and the new strategy with these partners. It's a little difficult sometimes for you guys to get line of sight on what may come, but we're intending to do more, and we're excited about what we're seeing.
Okay, good. C. diff, that's your internal pipeline, and then you did generate very interesting data so far. What's next for the clinical development, and is that also up for partnership if you get what stage you will start to think about the partnership?
Go ahead, Bob.
Thanks John , . We're also very excited about this particular candidate. We're excited because C. diff is a field that has a tremendous medical need and large burden of illness. There's no current vaccine available, and we believe our candidate is differentiated from the most advanced candidate in clinical development currently. We have a pentavalent, it's targeting both toxin and non-toxin antigens. We have Matrix-M in addition to increase the immunogenicity and induce mucosal immunity, mucosal IgA in the gut, which is what most experts in the field agree is the immune marker that probably is most important. The vaccine is designed intentionally to cover more than 90% of circulating strains of C. diff. They use the term ribotypes, circulating strains of C. diff. For all those reasons, we believe that we have a differentiated product.
We're very happy with the preclinical data that you alluded to in terms of the consistency and the activity that we see. In terms of where we are in next steps, we have initiated the pre-IND process with the FDA, and so we are fully engaged and interacting with them. We've started GMP manufacturing of product in anticipation of starting a clinical trial, perhaps as early as 2027. In terms of our ultimate goal here, our intent is to license a C. diff vaccine, and that is what we believe will actually create the most value for this particular vaccine. We also have to wait and see as the data comes in. As we generate data, we'll continually evaluate what's the best path forward for the company.
Got it. Just a quick follow-up. At what stage you will start to consider the partnership? It will be earlier, or you will keep it a bit longer, or it's data-dependent?
You want to take that one, Elaine?
Yeah, it's a great question. I think we are obviously going to engage in discussions with partners as we start to see the data and what it looks like. That's path one, but I also think we're interested in a potential path two if we decide that we want to retain our rights and keep the product. I think that's something that we would also consider as well.
It's about optimizing the value, Roger. We'll see what the data tells us. From there, we'll see what's the best way to optimize value for our shareholders.
Yeah, excellent. Okay, maybe just last minute.
Yeah.
If, Jim, you can comment on the financial.
Yeah.
Then how all the strategy we describe, then it's supported by the financial strength, then if you can give us a comment, that would be great.
Well, certainly. I would also love to give John a chance to speak to some of those critical catalysts next year as well.
Yeah. So we will tag team on it, Jim. Go ahead.
Absolutely. One of the things we have done to create the environment to unlock a lot of value is financial stability. Over the past four years, John and this team really leading a transformation of this company from a commercial company to now an R&D technology company with all these great partners you are hearing about. Our intent is tied to many important financial objectives, including, let us make sure you have at least two years of cash at any time. You heard most recently, we have got at least three years. Hey, pay off those legacy APA liabilities by the first quarter of 2029. Non-GAAP profitability as early as 2029. Let us get that lean and agile model by 2028, $150 -$200 million. So what you are hearing is that financial discipline intersecting with all the innovation, right, that John, Elaine, Bob have described.
Awesome. Yeah.
Thank you, Jim. Roger, just to close out, you asked about 2027. If you look at near-term catalysts and what to expect in 2027 and beyond from the company, everyone should look to see when we announce new partnerships potentially. Equally important would be expanding existing partnerships, them leaning in, Pfizer selecting a second field perhaps. They have already selected their first. Novavax earning some initial milestones potentially in the future from Pfizer as they advance programs, assuming success there, right?
Look for us to generate data with existing vaccines that are commercialized with Matrix-M, to share some of that data selectively, to finish our first wave of preclinical experiments in oncology, collect all of the data that Elaine alluded to and that we are working on, and to share some of that selectively in the coming quarters as we learn more about where Matrix may be able to play a role in that emerging ecosystem for vaccines. Look for us to continue to reduce our costs. If you take a look at just near-term catalysts with our partner Sanofi alone, they are running that European trial now. Look for them to wrap that up and share the data and to make a file and for potential approval in Europe.
Right.
To start that trial in the U.S., to get the data readouts there, potentially file, with a potential launch in the U.S. and a milestone for us. We like to say 2027 and beyond, because all of these things are working in parallel. There is plenty of near-term catalysts to get excited about for Novavax, some of which we cannot share with you too far in advance. When those things happen in a material way, we intend to communicate them accordingly. Lots ahead. We have seen the future. We really like what we are building and where we are headed.
Okay. Excellent.
Thanks.